^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TRPH-222

    i
    Other names: TRPH-222, CD22-4AP, CAT-02-106
    Company:
    BMS, Catalent, Triphase Accelerator Corporation
    Drug class:
    Microtubule inhibitor, CD22-targeted antibody-drug conjugate
    Related drugs:
    almost2years
    RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL) (EHA 2022)
    TRPH-222 monotherapy resulted in robust and durable CRs in FL across dose levels where patients were able to discontinue TRPH-222 while remaining in remissions. Collectively, these characteristics of TRPH-222 are favorable for further development in the indolent lymphoma setting either as monotherapy or in combination with other anti-tumor agents in B-cell lymphoma patients.
    Clinical • P1 data • PK/PD data
    |
    CD22 (CD22 Molecule)
    |
    TRPH-222